Dr Andrew Nicol
Adjunct Associate Professor
School of Human Movement and Nutrition Sciences
Journal Articles
Nicol, Jennifer L., Woodrow, Carmel, Cunningham, Brent J., Mollee, Peter, Weber, Nicholas, Smith, Michelle D., Nicol, Andrew J., Gordon, Louisa G., Hill, Michelle M. and Skinner, Tina L. (2022). An individualized exercise intervention for people with multiple Myeloma—study protocol of a randomized waitlist-controlled trial. Current Oncology, 29 (2), 901-923. doi: 10.3390/curroncol29020077
Nicol, Jennifer L., Woodrow, Carmel, Burton, Nicola W., Mollee, Peter, Nicol, Andrew J., Hill, Michelle M. and Skinner, Tina L. (2020). Physical activity in people with multiple myeloma: associated factors and exercise program preferences. Journal of Clinical Medicine, 9 (10) 3277, 3277-11. doi: 10.3390/jcm9103277
Sanchez-Herrero, Alvaro, Calvo, Isabel A., Flandes-Iparraguirre, Maria, Landgraf, Marietta, Lahr, Christoph A., Shafiee, Abbas, Granero-Molto, Froilán, Saez, Borja, Mazo, Manuel M., Paiva, Bruno, de Juan Pardo, Elena, Nicol, Andrew, Prosper, Felipe, Bray, Laura J. and McGovern, Jacqui A. (2020). Engineering a humanised niche to support human haematopoiesis in mice: novel opportunities in modelling cancer. Cancers, 12 (8) 2205, 2205-23. doi: 10.3390/cancers12082205
Eiraku, Y., Terunuma, H., Yagi, M., Deng, X., Nicol, Andrew J. and Nieda, M. (2018). Dendritic cells cross talk with tumor antigen-specific CD8+T cells, Vγ9γδT cells, and Vα24NKT cells in patients with glioblastoma multiforme and in healthy donors. Clinical and Experimental Immunology, 194 (1), 54-66. doi: 10.1111/cei.13185
Nieda, Mie, Terunuma, Hiroshi, Eiraku, Yuuta, Deng, Xuewen and Nicol, Andrew J. (2014). Effective induction of melanoma-antigen-specific CD8+ T cells via Vγ9γδT cell expansion by CD56high+ Interferon-α-induced dendritic cells. Experimental Dermatology, 24 (1), 35-41. doi: 10.1111/exd.12581
Deng, Xuewen, Terunuma, Hiroshi, Nieda, Mie, Xiao, Weihua and Nicol, Andrew (2012). Synergistic cytotoxicity of ex vivo expanded natural killer cells in combination with monoclonal antibody drugs against cancer cells. International Immunopharmacology, 14 (4), 593-605. doi: 10.1016/j.intimp.2012.09.014
Tokuyama, Hirotake, Hagi, Tomomi, Mattarollo, Stephen R., Morley, Jacqueline, Wang, Qiao, So, Hang-Fai, Moriyasu, Fuminori, Nieda, Mie and Nicol, Andrew J. (2011). Vγ9Vδ2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs—Rituximab and trastuzumab. International Journal of Cancer, 129 (11), 2761-2761. doi: 10.1002/ijc.26281
Nicol, A. J., Tokuyama, H., Mattarollo, S. R., Hagi, T., Suzuki, K., Yokokawa, K. and Nieda, M. (2011). Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours. British Journal of Cancer, 105 (6), 778-786. doi: 10.1038/bjc.2011.293
Nicol, Andrew J., Tazbirkova, Andrea and Nieda, Mie (2011). Comparison of Clinical and Immunological Effects of Intravenous and Intradermal Administration of alpha-GalactosylCeramide (KRN7000)-Pulsed Dendritic Cells. Clinical Cancer Research, 17 (15), 5140-5151. doi: 10.1158/1078-0432.CCR-10-3105
Abe, Yu, Muto, Masato, Nieda, Mie, Nakagawa, Yasunori, Nicol, Andrew, Kaneko, Touru, Goto, Shigenori, Yokokawa, Kiyoshi and Suzuki, Kenshi (2009). Clinical and immunological evaluation of zoledronate-activated Vγ9γδ T-cell-based immunotherapy for patients with multiple myeloma. Experimental Hematology, 37 (8), 956-968. doi: 10.1016/j.exphem.2009.04.008
Tokuyama, Hirotake, Hagi, Tomomi, Mattarollo, Stephen R, Morley, Jacqueline, Wang, Qiao, Fai-So, Hang, Moriyasu, Fuminori, Nieda, Mie and Nicol, Andrew J. (2008). Vγ9Vδ2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs—Rituximab and trastuzumab. International Journal of Cancer, 122 (11), 2526-2534. doi: 10.1002/ijc.23365
Lickliter, J. D., Cox, J., McCarron, J., Martinez, N. R., Schmidt, C. W., Lin, H., Nieda, M. and Nicol, A. J. (2007). Small-molecule Bcl-2 inhibitors sensitise tumour cells to immune-mediated destruction. British Journal of Cancer, 96 (4), 600-608. doi: 10.1038/sj.bjc.6603599
Mattarollo, Stephen R., Kenna, Tony, Nieda, Mie and Nicol, Andrew J. (2007). Chemotherapy and zoledronate sensitize solid tumour cells to V γ9Vδ2T cell cytotoxicity. Cancer Immunology Immunotherapy, 56 (8), 1285-1297. doi: 10.1007/s00262-007-0279-2
Mattarollo, Stephen R., Kenna, Tony, Niedal, Mie and Nicol, Andrew J. (2006). Chemotherapy pretreatment sensitizes solid tumor-derived cell lines to V alpha 24(+) NKT cell-mediated cytotoxicity. International Journal of Cancer, 119 (7), 1630-1637. doi: 10.1002/ijc.22019
Lin, H., Nieda, M., Hutton, J. F., Rozenkov, V. and Nicol, A. J. (2006). Comparative gene expression analysis of NKT cell subpopulations. Journal of Leukocyte Biology, 80 (1), 164-173. doi: 10.1189/jlb.0705421
Lin, H, Nieda, M, Rozenkov, V and Nicol, AJ (2006). Analysis of the effect of different NKT cell subpopulations on the activation of CD4 and CD8 T cells, NK cells, and B cells. Experimental Hematology, 34 (3), 289-295. doi: 10.1016/j.exphem.2005.12.008
Crough, T., Purdie, D. M., Okai, M., Maksoud, A., Nieda, M. and Nicol, A. J. (2004). Modulation of human V alpha 24(+)V beta 11(+) NKT cells by age, malignancy and conventional anticancer therapies. British Journal of Cancer, 91 (11), 1880-1886. doi: 10.1038/sj.bjc.6602218
Crough, T, Nieda, M and Nicol, AJ (2004). Granulocyte colony-stimulating factor modulates alpha-galactosylceramide-responsive human V alpha 24(+) V beta 11(+) NKT cells. Journal of Immunology, 173 (8), 4960-4966. doi: 10.4049/jimmunol.173.8.4960
Lin, H, Nieda, M and Nicol, AJ (2004). Differential proliferative response of NKT cell subpopulations to in vitro stimulation in presence of different cytokines. European Journal of Immunology, 34 (10), 2664-2671. doi: 10.1002/eji.200324834
Nieda, M, Okai, M, Tazbirkova, A, Lin, H, Yamaura, A, Ide, K, Abraham, R, Juji, T, Macfarlane, DJ and Nicol, AJ (2004). Therapeutic activation of V alpha 24(+)V beta 11(+) NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood, 103 (2), 383-389. doi: 10.1182/blood-2003-04-1155
Tazbirkova, A., Okai, M., Horley, D. C., Crough, T. M., Maksoud, A., Nieda, M. and Nicol, A. J. (2003). Effects of leukapheresis protocol, cell processing and cryopreservation on the generation of monocyte-derived DC for immune therapy. Cytotherapy, 5 (1), 31-39. doi: 10.1080/14653240310000056
Kashiwase, K, Kikuchi, A, Ando, Y, Nicol, A, Porcelli, SA, Tokunaga, K, Omine, M, Satake, M, Juji, T, Nieda, M and Koezuka, Y (2003). The CD1d natural killer T-cell antigen presentation pathway is highly conserved between humans and rhesus macaques. Immunogenetics, 54 (11), 776-781. doi: 10.1007/s00251-002-0527-8
Henderson, RD, Rajah, T, Nicol, AJ and Read, SJ (2003). Posterior leukoencephalopathy following, intrathecal chemotherapy with MRA-documented vasospasm. Neurology, 60 (2), 326-328.
Okai, M, Nieda, M, Tazbirkova, A, Horley, D, Kikuchi, A, Durrant, S, Takahashi, T, Boyd, A, Abraham, R, Yagita, H, Juji, T and Nicol, A (2002). Human peripheral blood V alpha 24(+) V beta 11(+) NKT cells expand following administration of alpha-galactosylceramide-pulsed dendritic cells. Vox Sanguinis, 83 (3), 250-253. doi: 10.1046/j.1423-0410.2002.00217.x
Crough, T, Nieda, M, Morton, J, Bashford, J, Durrant, S and Nicol, AJ (2002). Donor-derived b2a2-specific T cells for immunotherapy of patients with chronic myeloid leukemia. Journal of Immunotherapy, 25 (6), 469-475. doi: 10.1097/00002371-200211000-00003
Nieda, M, Kikuchi, A, Nicol, A, Koezuka, Y, Ando, Y, Ishihara, S, Lapteva, N, Yabe, T, Tokunaga, K, Tadokoro, K and Juji, T (2001). Dendritic cells rapidly undergo apoptosis in vitro following culture with activated CD4(+) V alpha 24 natural killer T cells expressing CD40L. Immunology, 102 (2), 137-145. doi: 10.1046/j.1365-2567.2001.01175.x
Kikuchi, A., Nieda, M., Schmidt, C., Koezuka, Y., Ishihara, S., Ishikawa, Y., Tadokoro, K., Durrant, S., Boyd, A., Juji, T. and Nicol, A. (2001). In vitro anti-tumour activity of α-galactosylceramide-stimulated human invariant Vα24+NKT cells against melanoma. British Journal of Cancer, 85 (5), 741-746. doi: 10.1054/bjoc.2001.1973
Lapteva, N, Nieda, M, Ando, Y, Nicol, A, Ide, K, Yamaura, A, Hatta-Ohashi, Y, Egawa, K, Juji, T and Tokunaga, K (2001). Gene expression analysis in human monocytes, monocyte-derived dendritic cells, and alpha-galactosylceramide-pulsed monocyte-derived dendritic cells. Biochemical And Biophysical Research Communications, 289 (2), 531-538. doi: 10.1006/bbrc.2001.6003
Nieda, M, Nicol, A, Koezuka, Y, Kikuchi, A, Lapteva, N, Tanaka, Y, Tokunaga, K, Suzuki, K, Kayagaki, N, Yagita, H, Hirai, H and Juji, T (2001). TRAIL expression by activated human CD4(+)V alpha 24NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukema cells. Blood, 97 (7), 2067-2074. doi: 10.1182/blood.V97.7.2067
Takahashi, T., Nieda, M., Koezuka, Y., Nicol, A., Porcelli, S.A., Ishikawa, Y., Tadokoro, K., Hirai, H. and Juji, T. (2000). Analysis of human V alpha 24(+) CD4(+) NKT cells activated by alpha-glycosylceramide-pulsed monocyte-derived dendritic cells. Journal of Immunology, 164 (9), 4458-4464. doi: 10.4049/jimmunol.164.9.4458
Nicol, A. J., Nieda, M., Koezuka, Y., Porcelli, S., Tadokoro, K., Durrant, S. T. and Juji, T. (2000). Human invariant valpha24+ natural killer T cells activated by alpha-galactosylceramide (KRN7000) have cytotoxic antitumour activity through mechanisms distinct from T cells and natural killer cells.. Immunology, 99 (2), 229-234. doi: 10.1046/j.1365-2567.2000.00952.x
Nicol, A. J., Nieda, M., Koezuka, Y., Porcelli, S., Suzuki, K., Tadokoro, K., Durrant, S. T. and Juji, T. (2000). Dendritic cells are targets for human invariant Valpha24+ natural killer T-cell cytotoxic: An important immune regulatory function. Experimental Hematology, 28 (3), 276-282. doi: 10.1016/S0301-472X(99)00149-6
Nieda, M, Nicol, A, Koezuka, Y, Kikuchi, A, Takahashi, T, Nakamura, H, Furukawa, H, Yabe, T, Ishikawa, Y, Tadokoro, K and Juji, T (1999). Activation of human V alpha 24NKT cells by alpha-glycosylceramide in a CD1d-restricted and V alpha 24TCR-mediated manner. HUMAN IMMUNOLOGY, 60 (1), 10-19. doi: 10.1016/S0198-8859(98)00100-1
Nieda, M., Nicol, A. J., Koezuka, Y., Kikuchi, A., Takahashi, T., Nakamura, H., Furukawa, H., Yabe, T., Ishikawa, Y., Tadokoro, K. and Juji, T. (1999). Activation of human Valpha24NKT cells by alpha-glycoslceramide in a CD1d-restricted and Valpha24TCR-mediated manner. Human Immunology, 60 (1), 10-19. doi: 10.1016/S0198-8859(98)00100-1
Denning-Kendall, P.A., Nicol, A., Horsley, H., Donaldson, C., Bradley, B. and Hows, J.M. (1998). Is in vitro expansion of human cord blood cells clinically relevant?. Bone Marrow Transplantation, 21 (3), 225-232. doi: 10.1038/sj.bmt.1701078
Nieda, Mie, Nicol, Andrew, Kikuchi, Akiko, Kashiwase, Koichi, Taylor, Kerry, Suzuki, Kenji, Tadokoro, Kenji and Juji, Takeo (1998). Dendritic cells stimulate the expansion of bcr-abl specific CD8(+) T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia. Blood, 91 (3), 977-983.
Denning-Kendall, P. A., Horsley, H., Nicol, A., Nieda, M., Bradley, B. and Hows, J. M. (1998). Clinical application of in vitro expansion of cord blood. Bone Marrow Transplantation, 22 (Suppl 1), S63-S65.
Nieda, Mie, Nicol, Andrew, Denning-Kendall, Patricia, Sweetenham, John, Bradley, Ben and Hows, Jill (1997). Endothelial cell precursors are normal components of human umbilical cord blood. British Journal of Haematology, 98 (3), 775-777. doi: 10.1046/j.1365-2141.1997.2583074.x
Donaldson, C., Armitage, W.J., Denning-Kendall, P.A., Nicol, A.J., Bradley, B.A. and Hows, J.M. (1996). Optimal cryopreservation of human umbilical cord blood. Bone Marrow Transplantation, 18 (4), 725-731.
Denning-Kendall, P., Donaldson, C., Nicol, A., Bradley, B. and Hows, J. (1996). Optimal processing of human umbilical cord blood for clinical banking. Experimental Hematology, 24 (12), 1394-1401.
Nicol, Andrew, Nieda, Mie, Donaldson, Craig, Denning-Kendall, Patricia, Truman, Carol, Bradley, Ben and Hows, Jill (1996). Cryopreserved human bone marrow stroma is fully functional in vitro. British Journal of Haematology, 94 (2), 258-265. doi: 10.1046/j.1365-2141.1996.d01-1812.x
Hows, J., Nicol, A., DenningKendall, P., Donaldson, C., Nieda, M. and Bradley, B. (1996). Cord blood as an alternative source of haemopoietic stem cells. Annals of Oncology, 7 (Suppl 2), 47-51. doi: 10.1093/annonc/7.suppl_2.47
Nicol, A., Nieda, M., Donaldson, C., DenningKendall, P., Bradley, B. and Hows, J. (1995). Analysis of cord blood CD34+ cells purified after cryopreservation. Experimental Hematology, 23 (14), 1589-1594.
Körner, R.J, Nicol, A., Reeves, D.S., MacGowan, A.P and Hows, J. (1994). Ciprofloxacin resistant Serratia marcescens endocarditis as a complication of non-Hodgkin's lymphoma. Journal of Infection, 29 (1), 73-76. doi: 10.1016/S0163-4453(94)95141-1
Nicol, Andrew J., Hows, Jill M. and Bradley, Benjamin A. (1994). Cord blood transplantation: a practical option?. British Journal of Haematology, 87 (1), 1-5. doi: 10.1111/j.1365-2141.1994.tb04862.x
Conference Papers
Nicol, Jennifer, Woodrow, Carmel, Burton, Nicola, Hill, Michelle, Skinner, Tina, Mollee, Peter and Nicol, Andrew (2019). Development of an individualized, supervised exercise intervention as standard care for patients with Multiple Myeloma. 17th International Myeloma Workshop, Boston, MA, United States, 12-15 September 2019. New York, United States: Elsevier. doi: 10.1016/j.clml.2019.09.355
Nicol, Andrew, Nieda, Mie, Hagi, Tomomi, Nicol, Jennifer and Choudhury, Aniruddha (2011). Addition of alpha-Galactosylceramide to tumor pulsed dendritic cell vaccines enhances tumor antigen-specific T cell responses and leads to clinical responses in patients with metastatic melanoma. 26th Annual Scientific Meeting of the Society for Immunotherapy of Cancer, North Bethesda, MD, United States, 4-6 November 2011. Philadelphia, PA, United States: Lippincott Williams & Wilkins. doi: 10.1097/CJI.0b013e318234180b
Kenealy, MK, Seymour, JF, Linda, C, Milner, A, Benson, W, Nicol, A, Campbell, P, Prosser, I, Underhill, C, Cunningham, I, Mills, AK, Szer, J, Presgrave, P and Filshie, R (2009). The Tolerability of Combination Therapy with Thalidomide and 5-Azacitidine in Patients with Advanced Myelodysplastic Syndromes (MDS).. 51st Annual Meeting of the American-Society-of-Hematology, New Orleans LA, DEC 05-08, 2009.
Takahara, M., Miyai, M., Tomiyama, M., Mutou, M., Nicol, A.J. and Nieda, M. (2008). Copulsing tumor antigen-pulsed dendritic cells with zoledronate efficiently enhance the expansion of tumor antigen-specific CD8+ T cells via Vy9y T cell activation. USA: Federation of American Societies for Experimental Biology. doi: 10.1189/jlb.0307185
Giles, N., Henry, J., Horley, D. and Nicol, A. J. (1999). Dendritic cell (DC) therapy for patients with solid tumors. Royal Brisbane Hospital Health Care Symposium, Westpac Auditorium Bancroft Cen., QIMR, Brisbane, 21 - 27 Oct, 1999. Brisbane: Royal Brisbane Hospital.
Nicol, A. J., Kikuchi, A., Nieda, M., Schmidt, C., Giles, N., Horley, D., Henry, J. and Durrant, S. T. (1999). Human Va24+ NKT cells have anti-tumour activity against human melanoma. Royal Brisbane Hospital Health Care Symposium, Westpac Auditorium Bancroft Cen., QIMR, Brisbane, 21 - 27 Oct, 1999. Brisbane: Royal Brisbane Hospital.
Nicol, A. J., Kikuchi, A., Nieda, M., Hutchins, C., Horley, D., Henry, J. and Durrant, S. T. (1999). Cytotoxic T-Lymphocyte therapy for a patient with chronic myeloid leukaemia. Royal Brisbane Hospital Health Care Symposium, Westpac Auditorium Bancroft Cen., QIMR, Brisbane, 21 - 29 Oct, 1999. Brisbane: Royal Brisbane Hospital.